Fadul, Camilo E.
Thakur, Archana
Kim, Jungeun
Kassay-McAllister, Jessica
Schalk, Dana
Lopes, M. Beatriz
Donahue, Joseph
Purow, Benjamin
Dillon, Patrick
Le, Tri
Schiff, David
Liu, Qin
Lum, Lawrence G.
Funding for this research was provided by:
Brain Institute at the University of Virginia
National Cancer Institute (P30CA022453, P30CA022453, P30CA022453, P30CA022453)
University of Virginia Cancer Center
National Cancer Institute, USA (R01 CA 182526, R01 CA 182526, R01 CA 182526, R01 CA 182526)
Article History
Received: 13 December 2023
Accepted: 3 January 2024
First Online: 23 January 2024
Declarations
:
: This protocol was approved by the University of Virginia (UVA) Institutional Review Board (IRB-HSR: 20105) and conducted according to the International Standards of Good Practice. All patients provided written informed consent to participate at enrollment.
: Not applicable.
: LGL is the founder of BATs, LLC and a co-founder of Transtarget, Inc. and serves on the Scientific Advisory Board of Rapa Therapeutics and Tundra Targeted Therapeutics. AT is a cofounder of AlphaImmune LLC. The other authors disclosed no potential conflicts of interest.